A Study of NeoRecormon in Patients With Chronic Kidney Disease.
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the level of anemia, and the decline in renal function, between
patients receiving NeoRecormon, and those not receiving it. Patients with chronic kidney
disease, stage 2-4, and not receiving dialysis, will be randomized 2:1 to a group receiving
NeoRecormon (at a dose determined by the investigator to achieve and maintain an Hb level of
120-135 g/L), or to a control group not receiving NeoRecormon. The anticipated time on study
treatment is 3-12 months, and the target sample size is <100 individuals.